ArticleEuropean journal of pediatrics2026
Health-related quality of life in children with Familial Mediterranean Fever: a Pediatric Quality of Life Inventory-based evaluation with mutation-specific analysis.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean Fever (FMF) is a chronic autoinflammatory disease that may adversely affect health-related quality of life (HRQoL) in childhood. The relative contributions of age, inflammatory burden, and MEFV mutation type to HRQoL impairment remain incompletely clarified. This cross-sectional study included 100 children with FMF and 70 age- and sex-matched healthy controls. HRQoL was assessed using the Pediatric Quality of Life Inventory (PedsQL™) child self-report (ages ≥ 8 years) and parent proxy-report forms. PedsQL scores were compared between groups and across age categories and mutation types. Receiver operating characteristic analysis was performed to determine cut-off values for impaired HRQoL, and multivariate logistic regression was used to identify independent predictors. Total and subscale PedsQL scores were significantly lower in children with FMF compared with controls, particularly in the 8-12 and 13-18 age groups (p < 0.001). Strong correlations were observed between child- and caregiver-reported scores. An overall PedsQL total score < 86 was identified as the optimal cut-off for poor HRQoL. In multivariate analysis, age 8-12 years and elevated C-reactive protein levels (> 3 mg/L) were identified as independent predictors of impaired HRQoL. No significant independent association was observed between MEFV mutation subgroups and HRQoL.
conclusionHRQoL is significantly reduced in children with FMF, particularly in those aged 8-12 years and in patients with evidence of ongoing inflammatory activity. Inflammatory markers rather than mutation type were associated with impaired HRQoL in this cohort. These findings underscore the importance of routine HRQoL assessment in the clinical follow-up of pediatric FMF patients. WHAT IS KNOWN: • Familial Mediterranean Fever (FMF) is a chronic autoinflammatory disease that can negatively affect health-related quality of life in children. • Previous studies have reported impaired quality of life in FMF; however, the relative impact of age, subclinical inflammation, and mutation status remains unclear. WHAT IS NEW: • This study demonstrates that impaired quality of life in pediatric FMF was independently associated with age (8-12 years) and elevated CRP levels rather than MEFV mutation type. • A clinically meaningful Pediatric Quality of Life Inventory (PedsQL) cut-off value is proposed to help identify children at risk for poor quality of life during routine follow-up.
Indexed as
Identifiers
41874655What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.